Pioneering ApproachesDelivering Innovation
We are committed to alleviating human suffering through the development of novel therapies.
We have a marketed product, DACOGEN®, indicated for the treatment of myelodysplastic syndromes. Dacogen is marketed by Eisai in North America and Janssen Cilag GmbH, International, a Johnson & Johnson company, in the rest of the world. Additionally, DACOGEN® has been approved in the European Union to treat adults aged 65 or older with acute myeloid leukemia (AML), a type of cancer affecting the white blood cells. It is used in elderly patients with newly diagnosed AML who are not eligible for initial treatment with standard chemotherapy.
And, as an innovative leader in small-molecule drug discovery, we have a strong portfolio of proprietary and partnered drug products that are in clinical development.